Alivus Life Sciences Ltd · NSE:ALIVUS
Alivus Life Sciences — Glenmark Life Sciences — Q3 FY22 Earnings Presentation
19 slides from Alivus Life Sciences's earnings presentation, Feb 8, 2022
Slide 1: Glenmark Life Sciences cover letter to exchanges
G qtenma~k LIFE SCIENCES Part nership. Innovation. Passion. February 08, 2022 To, To, Dy. General Manager The Manager - Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Sandra Kurla Complex, Fort, Mumbai -
Slide 2: Q3 FY22 Investor Presentation
Q3 FY22 Investor Presentation Glenmark Life Sciences Ltd G qlenma~k LIFE SCIENCES
Slide 3: Financial Performance Review
01 Financial Performance Review G qlenma~k LIFE SCIENCES
Slide 4: Q3 FY22 Highlights
Q3 Q3 FY22 FY22 -– Highlights Highlights • YoY Revenue grew at 4.5% in Q3 and Dr. Yasir Rawjee Revenue Managing Director 13.5% in 9M FY 22. INR 5,225 mn and Chief • CDMO business is growing at 45.1% Executive Officer in Q3 and 30.9% in 9M FY 22 t YoY, 4.5% l QoQ, -7.0% “We have delivered a steady pe
Slide 5: P&L Highlights - Q3 & 9M FY22
P&L P&L Highlights Highlights -– Q3 Q3 & & 9M 9M FY22 FY22 Amounts in INR Millions Q3 FY22 Q2 FY22 QoQ Q3 FY21 YoY 9M FY22 9M FY21 YoY Revenue from Operations 5,225 5,618 -7.0% 5,002 4.5% 16,092 14,180 13.5% Gross Profit 2,653 2,905 -8.7% 2,566 3.4% 8,214 7,050 16.5% Gross Profit (%) 50.8% 51.7% 51.
Slide 6: Quarter on Quarter Performance
Quarter on Quarter Performance Sustaining a profitable growth trajectory r----------------------------------- r----------------------------------- 36.4% 5,618 3 7 . 0 % 31.0% 28.6% 5,249 31.3% 30.2% 5,225 3 2 . 0 % 5,002 4,672 1 ,5 0 0 2 7 . 0 % 2 2 . 0 % 1,702 1,694 1 7 . 0 % 1,644 1 ,0 0 0 1,552 1
Slide 7: Financial Performance Track Record
Financial Performance Track Record Robust growth and profitability indicators over the years r----------------------------------- 18,852 r----------------------------------- 3 5 . 0 % 31.5% 31.4% 6 ,0 0 0 30.6% 30.0% 16,092 15,373 14,050 27.6% 3 0 . 0 % 5 ,0 0 0 12,017 2 5 . 0 % 4 ,0 0 0 5,919 2 0 .
Slide 8: Strong Returns Indicators
Strong Returns Indicators ~------------------------------· ROCE ~------------------------------· Fixed Assets Turnover ------------------------ Working Capital Days 33% FY19 FY20 FY21 9M FY22 33% 3.6 3.3 3 5 0 2 5 0 32% 202 2.9 - 176 3 0 0 173 2 0 0 2.7 152 31% 31% 2 5 0 2.5 98 1 5 0 2 0 0 1 5 0 104
Slide 9: Business Performance Review
02 Business Performance Review G qlenma~k LIFE SCIENCES
Slide 10: Segment Performance
Segment Segment Performance Performance 0.9% YoY -6.6% QoQ 45.1% YoY -17.3% QoQ 5,047 Revenue (₹ Mn) 4,675 4,803 4,715 Revenue (₹ Mn) 4,078 548 490 389 406 ■ 280 > Generic API Q3 FY21 Q4 FY21 Q1 FY22 Q2 FY22 Q3 FY22 CDMO > Q3 FY21 Q4 FY21 Q1 FY22 Q2 FY22 I Q3 FY22 • Generic API revenues in Q3FY22 1'
Slide 11: Market and Therapeutic Area Mix
Market and Therapeutic Area Mix 24% 27% 24% 27% 33% 35% 35% 37% 37% 44% 5% 6% 4% 4% 4% 7% 8% 14% 3% 6% 4% 7% 10% 14% 18% 76% 73% 76% 63% 67% 44% 47% 40% 39% 37% Market ....___________) Mix Q3 FY21 Q4 FY21 Q1 FY22 ■ Regulated Markets Q2 FY22 Q3 FY22 ■ Emerging Markets Therapeutic ....___________) Are
Slide 12: Company Overview
03 Company Overview G qlenma~k LIFE SCIENCES
Slide 13: Global Footprint
Global Footprint Filed 418 DMFs and CEPs across major markets; United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia ROW 50+ 330+ 30+ 83 113 145 10+ 16 100+ 50+ 61 (Brazil) India – Mix of Regulated Number of Number of customers Regulated Markets Emerging Mark
Slide 14: Quality-focused, compliant manufacturing & R&D infrastructure
Quality-focused, compliant manufacturing & R&D infrastructure Manufacturing Infrastructure R&D Infrastructure Annual Installed Capacity (Mar-21) Last USFDA Inspection Date Approvals Mahape, Navi Mumbai USFDA, MHRA (UK), FIMEA R&D for new product development (Finland), Romania (Europe) Ankleshwar,
Slide 15: R&D Capabilities
R&D Capabilities 429 - - ] [ ---- 405 4 5 0 5 .0 % 400 Cumulative Filing Status 4 0 0 376 4 .5 % 3 5 0 4 .0 % 3 0 0 3 .5 % North Therapy Europe Japan Brazil ROW Total 2 5 0 2.7% 2.6% 2.7% 3 .0 % America 2 0 0 2.1% 2 .5 % CVS 34 28 4 16 34 116 1 5 0 2 .0 % CNS 34 17 7 12 12 82 1 0 0 1 .5 % Diabetes 9
Slide 16: Strategy Going Forward
04 Strategy Going Forward G qlenma~k 15 LIFE SCIENCES
Slide 17: Strategic Growth Levers
Strategic Growth Levers • New product launches • Ramp up CDMO portfolio • Geographical expansion • Expand into complex API platforms • Focus on new markets becoming more • Iron compounds regulated • Oncology • Pursue 2nd source opportunities with top generic players Gx API New Growth Business levers
Slide 18: Future Capacity Expansion Plan
Future Capacity Expansion Plan Current Status & Planned Operational Expansion Type Division Location Capacity Capacity Timelines Under Construction Phase I – Q1FY23 Brownfield API Dahej 141.9 KL 4 Modules -240 KL Phase II – Q3 FY23 New plant Brownfield Intermediate Ankleshwar 550.2 KL Q2 FY23 400 KL
Slide 19: Thank You
Thank You Glenmark Life Sciences Limited Corporate Office: 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai, 400 099, India. Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur - 413 213, India. T: 91 22 68297979 CIN: U74900PN2011PLC13996
Glenmark Life Sciences — Q3 FY22 Earnings Presentation on 6ix